HOME >> MEDICINE >> NEWS
First study of Viagra(R) in black men demonstrates treatment as effective, well tolerated

ORLANDO, May 25, 2002 - In the first study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in black men with erectile dysfunction (ED), approximately eight out of 10 patients reported improvement in their erectile function and ability to have sexual intercourse after taking Viagra for six weeks, according to data scheduled to be presented at the annual meeting of the American Urological Association.

In this study of 246 black men, patients were randomly assigned to receive Viagra or placebo for six weeks, at which point they were given the choice to switch to the alternate treatment for another six weeks. At week six, a significantly larger percentage of Viagra-treated patients reported improved erections and improved ability to have sexual intercourse (79 percent and 81 percent) compared with placebo-treated patients (38 percent and 36 percent). Additionally, patient satisfaction was greater in the Viagra-treated group than in the placebo group.

Data also presented at the meeting by Culley Carson, M.D. of the University of North Carolina, Chapel Hill, examined the prevalence of ED in a nationally representative population sample of white, black and Hispanic American men, as defined by US census criteria, aged 40 and above. The study found that ED was a common problem among black men, with 24 percent of men reported to be only "sometimes" or "never" able to get and keep a satisfactory erection, compared to 22 percent of white and 20 percent of Hispanic men respectively.

Cardiovascular disease, high blood pressure and diabetes are all highly prevalent among black men. Because ED is often associated with such conditions, it is especially important to screen and treat black men who are experiencing erection problems," said Jean Bonhomme, M.D., Founder, National Black Men's Health Network. "We have now confirmed that Viagra is an effective and well tolerated treatment option for these men."

The prevalence study,
'"/>

Contact: Geoffrey Cook, Pfizer
212-733-5244
Porter Novelli
25-May-2002


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
Breaking Medicine Technology:
Cached News: